Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients
Sunwen Chou, Martha Fournier(Takeda (United States)), Rose Ann Murray(Takeda (United States)), Roy F. Chemaly(The University of Texas MD Anderson Cancer Center), Marcus R. Pereira(Columbia University), Sophie Alain(Inserm), Genovefa A. Papanicolaou(Memorial Sloan Kettering Cancer Center), Jens Lundgren(Centre of Excellence for Health, Immunity and Infections), Neil Buss, Camille N. Kotton(Harvard University), Jingyang J. Wu(Takeda (United States)), Carlos Cervera(University of Alberta)
Cited by 77
Related Papers
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
COVID-19 in solid organ transplant recipients: Initial report from the US epicenter
|American Journal of Transplantation|2020|837
Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy
|The Lancet Infectious Diseases|2017|822
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial
|Clinical Infectious Diseases|2021|299
Bacterial Populations Contaminating The Upper Gut in Patients With Small Intestinal Bacterial Overgrowth Syndrome
|The American Journal of Gastroenterology|1999|196